Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSEcnoglutide is a cAMP-biased peptide glucagon-like peptide 1 receptor (GLP-1R) agonist.1 It selectively induces cAMP accumulation over β-arrestin recruitment (EC50s = 0.018 and 1,300 nM, respectively) without inducing GLP-1R receptor internalization (EC50 = >10,000 nM) in cell-based assays using human GLP-1R. In vivo, ecnoglutide (0.15 mg/kg) reduces fasting and post-prandial blood glucose levels in db/db mice. It also reduces body weight and food intake in db/db mice when administered at a dose of 0.05 mg/kg.
WARNING This product is not for human or veterinary use.
1. Discovery of ecnoglutide — A novel, long-